Fostamatinib in Immune Thrombocytopenia

EP: 1.Treatment of Early Immune Thrombocytopenia (ITP)

EP: 2.Debate Regarding Upfront Treatment of Immune Thrombocytopenia

EP: 3.Immune Thrombocytopenia Treatment, COVID, and Other Vaccinations

EP: 4.Role of Splenectomy in Immune Thrombocytopenia Treatment

Now Viewing

EP: 5.Fostamatinib in Immune Thrombocytopenia

EP: 6.Treatment of Older Patients With ITP

EP: 7.ITP Treatment in Pregnancy

EP: 8.Challenges With Diagnosis of ITP

EP: 9.Sequencing in ITP

EP: 10.Experimental Agents for ITP

EP: 11.Key Takeaways From Discussion

James Bussel, MD: We had talked about changing to a different type of patient, so the use of rituximab up front, begging the questions about the COVID-19 era, would be less relevant. Let me mention that fostamatinib has been used as an anti-inflammatory agent for COVID-19 without the consideration of thrombocytopenia, which has been interesting. A preliminary pilot study from the NIH [National Institutes of Health] suggested it was effective. Additional studies are being pursued. Of the agents we’ve talked about for ITP [immune thrombocytopenic purpura], it probably has the more tolerability issues with causing high blood pressure and GI [gastrointestinal] adverse effects. But it can be very effective, even in TPO [thrombopoietin]–failure patients. It’s definitely been licensed since May 2018. It’s a very useful agent, especially if there’s a risk of thrombosis or if there’s a lot inflammation. But this needs to be fleshed out more.

Transcript Edited for Clarity